Compare Bank of New York Mellon Corp (BNY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Bank of New York Mellon Corp trades at $161 (market cap $108.17B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Bank of New York Mellon Corp pays a 1.39% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| BNY | VRTX | |
|---|---|---|
Market Cap | $108.17B | $132.79B |
Sector | Financials | Health |
52-Week High | $162.35 | $529.65 |
52-Week Low | $101.00 | $376.62 |
Dividend Yield | 1.39% | — |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY trades at $157.65, down 0.75% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.46 exceeding expectations. Revenue and net income have shown steady growth, with 2025 revenue at $19.76 billion and net income at $5.55 billion. Recent news highlights BNY's expansion into digital transfer agency capabilities and a strategic collaboration with Galaxy Digital to advance digital asset infrastructure, signaling innovation in fund servicing.
The outlook for BNY is positive, supported by strong earnings performance, a consensus price target of $170.36, and a bullish analyst rating upgrade to Strong Buy by Zacks. Investment opportunities include continued revenue growth and margin expansion. Risks involve high investing cash outflows, competitive pressures in custody banking, and sensitivity to interest rate changes. The stock offers a dividend yield with recent increases, appealing to income-focused investors amid solid fundamentals.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
